Calamos Advisors
CRNX icon

Calamos Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

Calamos Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,402
Closed -$736K – 922
2024
Q4 		$736K Sell
14,402
-27,156
-65% -$1.52M ﹤0.01% 696
2024
Q3 		$2.12M Sell
41,558
-778
-2% -$40.1K 0.01% 610
2024
Q2 		$1.9M Buy
42,336
+13,336
+46% +$616K 0.01% 593
2024
Q1 		$1.36M Buy
+29,000
New +$1.13M 0.01% 613

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Calamos Advisors's CRNX Position: Q1 2025 in Review

Calamos Advisors sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2025, closing a stake of 14,402 shares — an estimated $736K sold.

Calamos Advisors first reported a position in CRNX in Q1 2024 and held it in 4 quarters. The position peaked at $2.12M in Q3 2024. 227 funds tracked by Wall St. Rank hold CRNX as of Q1 2025.

  • Calamos Advisors reported no remaining Crinetics Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Calamos Advisors sold 14,402 Crinetics Pharmaceuticals shares in Q1 2025, an estimated $736K.
  • Calamos Advisors first reported a position in Crinetics Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Calamos Advisors's Crinetics Pharmaceuticals position peaked at $2.12M in Q3 2024.
  • 227 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2025.

Based on Calamos Advisors's 13F filing for Q1 2025, filed 29 Apr 2025.